Moscow could place nuclear weapons in Syria to counter Turkey: analysts
DEBKAfile November 24, 2015, 6:42 PM (IDT)
Leading Russian military commentators in Moscow said Tuesday evening that Russia could place nuclear weapons in Syria if tension with Turkey continues to rise. When asked by a Western interviewer if such a situation could actually happen, one commentator said it is now considered to be a real possibility.
The reason given by BARDA, according to Venkat, was that BARDA did not agree that Cleveland's proposed studies were the proper ones to achieve FDA approval – an explanation difficult to understand in light of the FDA's ongoing communication and involvement with the company. Venkat described the letter from BARDA as "short," containing about half a page of positive statements about CBLB502, and another half-page of concerns on whether the proposed studies were the correct studies to undertake.
"My personal feeling is that BARDA is clearly anticipating and awaiting the . . . determinations that are going to come in the meetings that we have on the second day with the FDA," Venkat said. Those meetings would eliminate any uncertainty about what studies will be acceptable for approval.
Well to keep the momentum going, and after so many setbacks, let's look optimistically at the next six months:
1.) The second $5m - $6M funding piece by 9/30/15;
2.) Pre-EUA status granted by December;
3) Publication of Entolimod Phase 1 Oncology results;
Which will hopefully set the stage for a partnership to advance Entolimod as an adjunct to one of the immune checkpoint inhibitors. I cannot determine which one of the current drug prospects would benefit most from adding a "mod" to the "mAb" but it seems like there are many candidates. So Entolimod either gives new legs to an existing drug or provides the response and efficacy that a big Pharma candidate needs to move forward.